BioCentury | Aug 31, 2017
Targets & Mechanisms

Necroptosis strikes again

...in ALS. Denali Therapeutics Inc. gained the rights to Yuan's RIPK1 program when it acquired Incro Pharmaceuticals Corp....
BioCentury | Sep 12, 2016
Strategy

Dealing Denali

...the deals announced on Aug. 25 add three first-in-class pipeline programs from Genentech Inc. , Incro Pharmaceuticals Corp....
BioCentury | Sep 5, 2016
Company News

Incro Pharmaceuticals, Denali Therapeutics deal

...rights to the program from Harvard University (Cambridge, Mass.). Denali declined to disclose financial terms. Incro Pharmaceuticals Corp....
BioCentury | Aug 25, 2016
Top Story

Denali unveils $130M funding, series of deals

...future trials in AD and ALS. The company gained the program through its acquisition of Incro Pharmaceuticals...
Items per page:
1 - 4 of 4
BioCentury | Aug 31, 2017
Targets & Mechanisms

Necroptosis strikes again

...in ALS. Denali Therapeutics Inc. gained the rights to Yuan's RIPK1 program when it acquired Incro Pharmaceuticals Corp....
BioCentury | Sep 12, 2016
Strategy

Dealing Denali

...the deals announced on Aug. 25 add three first-in-class pipeline programs from Genentech Inc. , Incro Pharmaceuticals Corp....
BioCentury | Sep 5, 2016
Company News

Incro Pharmaceuticals, Denali Therapeutics deal

...rights to the program from Harvard University (Cambridge, Mass.). Denali declined to disclose financial terms. Incro Pharmaceuticals Corp....
BioCentury | Aug 25, 2016
Top Story

Denali unveils $130M funding, series of deals

...future trials in AD and ALS. The company gained the program through its acquisition of Incro Pharmaceuticals...
Items per page:
1 - 4 of 4